CELYNTRA THERAPEUTICS

Active

Public limited companyfounded 2019active for 6 yearsRue Edouard Belin 2, 1435 Mont-Saint-Guibert, BelgiumKBO/BCE: BE 0737.829.015

From the official registers: KBO 7 annual accounts at the National Bank publications in the Belgian Official Gazette

Summary

The computed 12-month bankruptcy probability of CELYNTRA THERAPEUTICS is 3.2% (moderate). The 2025 annual accounts show negative equity (-€9.6m) and a net result of -€3.1m. The figures fluctuate too strongly year-on-year for a reliable trend projection. Its solvency ranks better than 5% of 6,158 sector peers (NACE 46, financial year 2025). The company has been active since 2019 and the Belgian Official Gazette contains no insolvency or warning signals.

Risk analysisFollow Report Compare

CELYNTRA THERAPEUTICSActiveChecked score 47/100

Risk analysis Report Compare

Official details

KBO

Status: Active since 19-11-2019 Normal situation
Legal form: Public limited company
Registered office: Rue Edouard Belin 2, 1435 Mont-Saint-Guibert
Activity: Wholesale of pharmaceutical and medical goods NACE 46460
Establishment unit: 2.299.080.043 1435 Mont-Saint-Guibert, since 19-11-2019
Financial year end: 31 December
Peppol: Reachable since 27-11-2025

Company details

Who decides

Board

Jason ConnerDirector · since 05-03-2026

Auditor: PwCReviseurs d'Entreprises SRL

Shareholders

Ncardia Holding0%annual accounts 2025

Board & ownership

How it is doing

47 Fair Checked score 2025

Bankruptcy probabilitywithin 12 months: 3.2%

Annual accounts 2025

Gross margin: €560,992
Turnover: ≈ €2.8m; estimated
Loss: €3.1m; ▼ 52.1%
Equity: -€9.6m; ▼ 40.1%
Total assets: €8.2m; ▲ 3.4%
Staff: 12.7 FTE; =

2025 accounts 51 days early

Filed on 10-06-2026PDF

Financials

Why 47raises riskNegative equity -€9.6mLoss of €3.1m, the second in a row (financial year 2025)Liquidity: current ratio 0.13, cash €445,0461 of the last 3 lateShow the evidence

Checked score

Score 2025

47 / 100

Fair

Probability in this band: 1.5% to 4.2%

Financially better than 4% of its sector peers (NACE 46, small)

Every signal that counts is listed under Signals.

Financial strength · tick = 2024

Weak

Solvency 0=

equity -117.1% of total assets

Liquidity 7+5

short-term debt 215.2% · cash 5.4%

Profitability 0=

return on assets -37.4%

Bankruptcy probability, 12 months

3.2% Moderate

0%0.5%1.5%4%10%≥ 25%

About 3 in 100 comparable companies go bankrupt within 12 months (an estimate).

Sector median 0.2% (4,376 companies, NACE 46, small)

Last 24 months 11-2024: 1.4% 12-2024: 1.4%● unchanged vs 11-2024 01-2025: 1.3%▼ -0.1 percentage points vs 12-2024 02-2025: 1.3%● unchanged vs 01-2025 03-2025: 1.5%▲ +0.2 percentage points vs 02-2025 04-2025: 0.8%▼ -0.7 percentage points vs 03-2025lowest value 05-2025: 0.9%▲ +0.1 percentage points vs 04-2025 06-2025: 1.0%▲ +0.1 percentage points vs 05-2025 07-2025: 1.0%● unchanged vs 06-2025 08-2025: 1.4%▲ +0.4 percentage points vs 07-2025 09-2025: 1.6%▲ +0.2 percentage points vs 08-2025 10-2025: 2.6%▲ +1.0 percentage point vs 09-2025 11-2025: 4.6%▲ +2.0 percentage points vs 10-2025 12-2025: 4.6%● unchanged vs 11-2025 01-2026: 4.7%▲ +0.1 percentage points vs 12-2025 02-2026: 5.2%▲ +0.5 percentage points vs 01-2026 03-2026: 5.1%▼ -0.1 percentage points vs 02-2026 04-2026: 5.1%● unchanged vs 03-2026 05-2026: 5.2%▲ +0.1 percentage points vs 04-2026 06-2026: 5.3%▲ +0.1 percentage points vs 05-2026highest value 07-2026: 3.2%▼ -2.1 percentage points vs 06-2026 08-2026: 3.2%● unchanged vs 07-2026 09-2026: 3.2%● unchanged vs 08-2026 10-2026: 3.2%● unchanged vs 09-2026

No credit on open account

Liquidity insufficient (current ratio 0.13, compared with 0.14 in 2024, below 1; short-term debt: 215.2% and cash: 5.4% of total assets), and equity is negative.

How it is calculated

The band follows from the bankruptcy probability, on a scale where 10 more points roughly halve it:

75-100	Excellent	under 0.55%
60-74	Healthy	0.55% to 1.5%
45-59	Fair	1.5% to 4.2%
25-44	Weak	4.2% to 15.0%
0-24	Critical	over 15.0%

Where the company stands within its band depends half on the bankruptcy probability and half on how it does against its sector peers (NACE 46, small): better than 1% on solvency, 6% on liquidity, 1% on profitability and 6% on growth.

The bankruptcy probability was computed on 31-10-2026 by the bankruptcy model of 2 October 2026, which learns from Belgian bankruptcies and reads the registers, the annual accounts and the Belgian Official Gazette.

Some facts cap the score, however low the probability. Negative or zero equity, a heavy loss, a special status in the KBO, one missing filing or accounts filed more than 90 days late hold it at Fair at most (59); two missing filings, at Weak (44). An ongoing judicial reorganisation or the company's end (bankruptcy, dissolution, liquidation) holds it at Critical at most (24).

Credit check for your own amount and term

Show the recommended maximum and see how the verdict changes with amount, term and advance.

Signals

Six signals.

raises riskneutral

Negative equity -€9.6m

NBB · annual accounts

Loss of €3.1m, the second in a row (financial year 2025)

NBB · annual accounts

Liquidity: current ratio 0.13, cash €445,046

NBB · annual accounts

1 of the last 3 late

NBB · filings

Negative equity

The 2025 annual accounts show negative equity and a net loss.

NBB · annual accounts 2025

Equity per financial year

19202122232425

2019 to 2025 · latest year -€9.6m

Latest accounts filed on time

The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 10-06-2026, 51 days ahead of the deadline.

NBB · 7 filings

Deviation from the deadline

2025

51 days early

2024

77 days late

2023

7 days early

2022

31 days early

2021

54 days late

2020

61 days late

2019

1 day early

← before the deadline after the deadline →

tick = median of all Belgian filingsring = median in the sector

This company filed its last 7 accounts on average 15 days after the deadline; the sector median (NACE 46) for financial year 2024 is 3 days before the deadline, and 39% of those companies filed late.

Searched, nothing found (2)

Next filing not due yet

The next financial year closes on 31-12-2026 and is due by 31-07-2027. Nothing is late today. The company usually files around 25 July (4 of the last 5 filed years within 60 days of that day).

Companies Code · seven months

Where today falls in the filing period

01-11-2026 today31-12-2026 year end31-07-2027 deadline

No strike-offs in the KBO publications

Searched since 2021.

KBO publications · our coverage

Key points

Risk: Negative equityfinancial year 2025: debts exceed assets -€9.6m View
Risk: 7 loss-making years in a rowloss financial year 2025 -€3.1m View
Caution: Among the weakest 5% on solvencysector median 45.2% · 6,158 companies -117.1% View
Caution: Board changedlatest change 07-05-2026 · 1 in office 1 joined · 1 left View
Positive: Result rose in 2025from -€6.4m to -€3.1m ▲ 52.1% View

Documents

Key facts about CELYNTRA THERAPEUTICS

What is the company number of CELYNTRA THERAPEUTICS?: 0737.829.015. In Belgium the VAT number is the company number with BE in front: BE 0737.829.015.
Where is CELYNTRA THERAPEUTICS based?: The registered office is at Rue Edouard Belin 2, 1435 Mont-Saint-Guibert.Company details
What does CELYNTRA THERAPEUTICS do?: According to the KBO register, the main activity is wholesale of pharmaceutical and medical goods (NACE 46460).
What is the legal form of CELYNTRA THERAPEUTICS?: Public limited company (NV).
When was CELYNTRA THERAPEUTICS founded?: On 19-11-2019.
Is CELYNTRA THERAPEUTICS still active?: Yes, CELYNTRA THERAPEUTICS is an active enterprise in the KBO register.
How many employees does CELYNTRA THERAPEUTICS have?: On average 12.7 full-time equivalents in financial year 2025, according to the filed annual accounts.Financials
What is the turnover of CELYNTRA THERAPEUTICS?: ≈ €2.8m in financial year 2025. Estimated from the gross margin of €560,992: probably between €2.1m and €4.3m, based on 37 comparable companies, NACE 464.
Is CELYNTRA THERAPEUTICS profitable?: In financial year 2025, CELYNTRA THERAPEUTICS made a loss of €3.1m.
Where can I find the annual accounts of CELYNTRA THERAPEUTICS?: CELYNTRA THERAPEUTICS filed 7 annual accounts with the National Bank of Belgium, the latest for financial year 2025.Annual accounts 2025 (PDF)
When are the next annual accounts of CELYNTRA THERAPEUTICS due?: By 31-07-2027, for financial year 2026.Timeline